Welcome to the e-CCO Library!

P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kurti Z.*1, Rutka M.2, Vegh Z.1, Gonczi L.1, Farkas K.2, Lovasz B.D.1, Gecse K.B.1, Golovics P.A.1, Szalay B.3, Molnar T.2, Lakatos P.L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P411: Early ultrasound assessment predicts therapy response: an easy tool for clinical decision making
Year: 2023
Source: ECCO’23 Copenhagen
Authors: CalabresePhD, E.(1)*;Castiglione, F.(2);De Cristofaro, E.(1);Rispo, A.(2);Capacchione , C.(1);Testa, A.(2);Guarino, A.D.(2);Caiazzo, A.(2);Monteleone, G.(1);Zorzi, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P411: Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Cassieri*1, R. Pica1, E. v. V. Avallone1, G. Brandimarte2, M. Zippi1, P. Crispino1, G. Lecca2, C. Corrado1, P. Vernia1, P. Paoluzi1, E. v. S. Corazziari1

Created: Friday, 22 February 2019, 9:49 AM
P411: Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
Year: 2022
Source: ECCO'22
Authors: Moore, A.C.(1);Russell, D.(1);Dart, R.(1,2);Dias, S.(1);Ghuman, S.(1);Petri, B.(1);Sharma, E.(1);Ray, S.(1);Anderson, S.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P411: Using wearable devices to assess pain in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. V. Yvellez*1, P. H. Sossenheimer1, M. Andersen Jr1, K. El Jurdi1, A. Mayampurath2, D. T. Rubin1

Created: Friday, 22 February 2019, 9:41 AM
P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Ito, M. Shun, O. Teppei, T. Katsutoshi

Created: Thursday, 30 January 2020, 10:12 AM
P412: Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.
Year: 2022
Source: ECCO'22
Authors: Ollech, J.(1);Yanai, H.(1);Avni-Biron, I.(1);Snir, Y.(1);Banai, H.(1);Broitman, Y.(1);Goren, I.(1);Wasserberg, N.(2);White, I.(2);Dotan, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
P412: Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNF
Year: 2021
Source: ECCO'21 Virtual
Authors: Carpio, D.(1);Calviño-Suarez , C.(2);Martínez-Cadilla , J.(3);Molina , G.(4);Vázquez-Rey , M.T.(5);Martí , E.(6);Fernández-Salgado , E.(1);Barreiro-de Acosta , M.(2);Hernández , V.(3);Echarri , A.(4);Diz-Lois , M.T.(5);Baz , A.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Arkenbosch*1, O. van Ruler2, W. Deijl2, J. Stevens3, A. de Vries4, J. van der Woude4, E. de Graaf2, R. Schouten1,2

Created: Friday, 22 February 2019, 9:41 AM
P412: Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazine
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Algaba*, I. Guerra, D. Bonillo, M. Hernández, A. Granja, P. Bernal, F. Berrmejo

Created: Friday, 22 February 2019, 9:49 AM
P412: The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Orlando A.1, Macaluso F.S.*1, Fries W.2, Privitera A.C.3, Cappello M.4, Siringo S.5, Inserra G.6, Magnano A.7, Di Mitri R.8, Belluardo N.9, Scarpulla G.10, Magrì G.11, Trovatello N.12, Carroccio A.13, Genova S.14, Calandruccio G.15, Vassallo R.16, Romano C.17, Pellegrino S.17, Citrano M.18, Accomando S.19, Ventimiglia M.1, Renna S.1, Orlando R.1, Rizzuto G.1, Vinci E.1, Cottone M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P412: Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Komatsu, K.(1)*;Shinagawa, T.(1);Noguchi, T.(1);Uchino, M.(2);Ikeuchi, H.(2);Okabayashi, K.(3);Tanaka, S.(4);Futami, K.(5);Itabashi, M.(6);Watanabe, K.(7);Nagahara, H.(8);Okita, Y.(9);Shimada, Y.(10);Mizuuchi, Y.(11);Okamoto, K.(12);Yamada, K.(13);Sato, Y.(14);Mizushima, T.(15);Kimura, H.(16);Takahashi, K.(17);Hida, K.(18);Kinugasa, Y.(19);Ishida, F.(20);Okuda, J.(21);Daito, K.(22);Yamamoto, T.(23);Yamamoto, S.(24);Koyama, F.(25);Hanai, T.(26);Komori, K.(27);Shida, D.(28);Arakaki, J.(29);Akagi, Y.(30);Yamaguchi, S.(31);Ueno, H.(32);Matsuda, K.(33);Ajioka, Y.(34);Sugihara, K.(35);Ishihara, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P412: White cell count (WCC) and mean corpuscular volume (MCV) as surrogate markers for thiopurine monitoring in inflammatory bowel disease (IBD) treatment: A single-centre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Christopher*, K. Altamimi, N. Campbell, R. Rynne-Lyons, A. Alakkari, A. O'Connor, D. McNamara, N. Breslin, B. Ryan

Created: Thursday, 21 February 2019, 9:14 AM
P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.A. Ruiz-Ramirez1, C. Suarez1, J. Poza1, E. Martin-Arranz1, J.L. Rueda-Garcia1, M. Sanchez-Azofra1, M. Cuadros1, P. Mayor1, L. Garcia-Ramirez2, M.D. Martin-Arranz1

Created: Thursday, 30 January 2020, 10:12 AM
P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. S. Dulai*1, A. Amiot2, L. Peyrin-Biroulet3, S. Singh1, M. Serrero4, V. Jairath5, J. Filippi6, B. Pariente7, E. V. Loftus Jr8, X. Roblin9, S. Kane8, A. Buisson10, C. A. Siegel11, Y. Bouhnik12, W. J. Sandborn1, K. Lasch13, M. Rosario13, B. G. Feagan5, D. Bojic14, C. Trang-Poisson15, B. Shen16, R. Altwegg17, B. E. Sands18, J-F. Colombel18, F. Carbonnel19, M. Bohm20, D. Hudesman21, A. Bourrier22, D. Lukin23, GETAID OBSERV-IBD and VICTORY Cohorts Collaboration1

Created: Friday, 22 February 2019, 9:41 AM
P413: Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)
Year: 2022
Source: ECCO'22
Authors: Tran, A.P.(1,2);Tassone, D.(3,4);Nossent, J.C.(2,5);Ding, N.S.(3,4);
Created: Friday, 11 February 2022, 3:52 PM
P413: Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ladrón Abia, P.(1); Alonso, N.(2);Beltrán, B.(1);Minguez, A.(1);Sáez-González, E.(1);Pons-Beltrán, V.(2);Nos, P.(1);Iborra, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P413: Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected cases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Asairinachan*, V. An, E. Daniel, M. Johnston, J. Keck, P. Salama, R. Woods

Created: Friday, 22 February 2019, 9:49 AM
P413: Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Heerasing N.*1, Thompson B.1, Hendy P.1, Heap G.1,2, Walker G.1,2, Bethune R.1, Calvert C.1, Kennedy N.1,2, Ahmad T.1,2, Goodhand J.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Fadeeva1*, O. Knyazev1, A. Kagramanova1, A. Babayan1, A. Lishchinskaya1, I. Ruchkina1, A. Konoplyannikov2, A. Parfenov1

Created: Thursday, 21 February 2019, 9:14 AM